Sacha Gnjatic, PhD
img_Sacha Gnjatic
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Pathology, Molecular and Cell Based Medicine
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
Research Topics
Anti-Tumor Therapy, Antigen Presentation, B Cells, Cancer, Cellular Immunity, Dendritic Cells, Immunological Tolerance, Immunology, Immunosuppression, Lung, Microarray, Proteomics, T Cells, Tolerance, Translation, Vaccine Development
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
Tissue immune microenvironment:
Assessment of the tumor microenvironment for immunocytes and suppressive signals, including development of novel spatial technologies to address in depth biomarkers at the tissue site.
Impact of immunoregulation on tumor antigen-specific responses:
Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells on anti-tumor effectors, and study of immune tolerance.
Immune monitoring to discover mechanisms and biomarker of cancer immunotherapies:
Multiscale (host, circulation, tissues, single cell), multiomics (immunophenotyping, immunopathology, immunotranscriptomics, bioinformatics) approaches for biomarker discovery and understanding of mechanisms contributing to clinical responses, adverse events, or primary and acquired resistance to tumor immunotherapies.
Inflammatory diseases:
Role of GM-CSF autoantibodies throughout Crohn's disease development. Dissecting role of cytokines, antibody and T cell responses in COVID-19 patients after infection or vaccination.
Mechanisms of antigen presentation to T cells:
Mechanisms of antigen presentation to and recognition by T cells, including defining epitopes, evaluating viral, bacterial, and parasitic vectors, cross-presentation of antigen to HLA class I, and endogenous antigen presentation to HLA class II.
Antigen-specific spontaneous and immunotherapy-induced tumor immunity:
Characterization of serological and cellular immune responses against tumor antigens such as NY-ESO-1, MAGE-A3, or p53, and for their capacity to induce immune responses both spontaneously and in the setting of cancer immunotherapy.

BSc3, University College London

MSc, Institut Pasteur

Undergraduate, Ecole Normale Supérieure

PhD, University Paris VII

Post-doc, Memorial Sloan-Kettering - Ludwig Institute

Publications

Selected Publications

Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. Joan Shang, Diane Marie Del Valle, Graham J. Britton, K. R. Mead, Urvija Rajpal, Alice Chen-Liaw, Ilaria Mogno, Zhihua Li, Rajita Menon, Edgar Gonzalez-Kozlova, Arielle Elkrief, Jonathan U. Peled, Tina Ruth Gonsalves, Neil J. Shah, Michael Postow, Jean Frederic Colombel, Sacha Gnjatic, David M. Faleck, Jeremiah J. Faith. Journal of Experimental Medicine

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Seong Keun Yoo, Conall W. Fitzgerald, Byuri Angela Cho, Bailey G. Fitzgerald, Catherine Han, Elizabeth S. Koh, Abhinav Pandey, Hannah Sfreddo, Fionnuala Crowley, Michelle Rudshteyn Korostin, Neha Debnath, Yan Leyfman, Cristina Valero, Mark Lee, Joris L. Vos, Andrew Sangho Lee, Karena Zhao, Stanley Lam, Ezekiel Olumuyide, Fengshen Kuo, Eric A. Wilson, Pauline Hamon, Clotilde Hennequin, Miriam Saffern, Lynda Vuong, A. Ari Hakimi, Brian Brown, Miriam Merad, Sacha Gnjatic, Nina Bhardwaj, Matthew D. Galsky, Eric E. Schadt, Robert M. Samstein, Thomas U. Marron, Mithat Gönen, Luc G.T. Morris, Diego Chowell. Nature Medicine

Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations. Rebecca T. Miceli, Tzu Yi Chen, Yohei Nose, Swapnil Tichkule, Briana Brown, John F. Fullard, Marilyn D. Saulsbury, Simon O. Heyliger, Sacha Gnjatic, Natasha Kyprianou, Carlos Cordon-Cardo, Susmita Sahoo, Emanuela Taioli, Panos Roussos, Gustavo Stolovitzky, Edgar Gonzalez-Kozlova, Navneet Dogra. Journal of Extracellular Vesicles

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Gnjatic during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Taiho Oncology, Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.